Non-Hodgkin's Lymphoma Typical Treatments

Treatment for Non-Hodgkin’s Lymphomas (NHL) differs from patient to patient. The regimen used depends on the type of NHL, the stage, and whether the disease is aggressive or indolent.

The following is a list of typical treatments:

Chemotherapy: Chemotherapy is the use of cytotoxic (cell damaging) medicines to target and kill tumors. The drugs work by interrupting the DNA of fast-growing cells, preventing them from growing or reproducing. Chemotherapy can lead to a variety of side effects.

Radiation: Radiation therapy uses high doses of X-rays, gamma rays, or other types of ionizing (damaging) radiation to kill cancer cells. It may be applied to the whole body or to a specific zone.

Immunotherapy: Immunotherapy uses the body’s own immune system to attack and remove cancer cells. Doctors inject a patient with a special type of antibody, or cell marker, that binds to antigens on a cell’s surface.

Radioimmunotherapy: (radiolabeled monoclonal antibodies) Radioimmunotherapy combines monoclonal antibody therapy with radioactive isotopes. Though it was developed in the 1980's, radioimmunotherapy is just now beginning to gain widespread acceptance. In the United States, it has been approved by the FDA for treatment of certain types of refractory lymphoma / relapsed lymphoma. The Zevalin® regimen has been approved by the FDA as a first-line treatment of certain follicular lymphoma patients.

Bone Marrow Transplantation: For patients with very advanced disease, extremely high does of chemotherapy may be needed. This type of chemotherapy wipes out the body’s entire immune system, including the bone marrow that produces blood cells. So, patients need a bone marrow transplant in order to recover.

Watch and Wait: This treatment option is used for patients with indolent, low-grade cancers in the early stages. In some cases, early stage cancers don’t respond well to treatment, so it’s more efficient to wait until the cancer has progressed to a treatable stage before prescribing chemotherapy and radiation.

Clinical Trials: New lymphoma treatment options are always being researched. If you wish to take part in a clinical trial, talk to your doctor.

These individual therapies may be combined for optimum treatment. Chemotherapy is often given in combination with radiation for advanced cancers, and some B-cell and T-cell cancers are treated with chemo and immunotherapy.

Clinical Trials

Patients who are looking for more advanced treatment or who have lymphoma that does not respond to standard treatment may want to consider a clinical study. Click here to find clinical trials in your area.

Photo: [SOURCE]

More Articles

More Articles

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Sitemap